Conjugated linoleic acid modulation of risk factors associated with atherosclerosis

Conjugated linoleic acid modulation of risk factors associated with atherosclerosis

Conjugated linoleic acid (CLA) has been the subject of extensive investigation regarding its possible benefits on a variety of human diseases. In some animal studies, CLA has been shown to have a beneficial effect on sclerotic lesions associated with atherosclerosis, be a possible anti-carcinogen, increase feed efficiency, and act as a lean body mass supplement. However, the results have been i...

Atherosclerosis and conjugated linoleic acid.

Atherosclerosis can be defined as the development of abnormal fat deposits in the artery wall. Atherosclerotic lesions are believed to progress through a focal, lipid-filled foam cell stage (fatty streak) into an advanced, complicated lesion that contains abundant extracellular cholesterol ester in the atheromatous gruel within the arterial intima. Weakening of the arterial wall and/or rupture ...

Conjugated linoleic acid suppresses IRF3 activation via modulation of CD14.

Polyunsaturated fatty acids (PUFA) can modulate the immune response, however the mechanism by which they exert this effect remains unclear. Previous studies have clearly demonstrated that the cis-9, trans-11 isomer of conjugated linoleic acid (c9,t11-CLA), found predominantly in beef and dairy products, can modulate the response of immune cells to the toll-like receptor (TLR) 4 ligand, lipopoly...

Conjugated Linoleic Acid Targets

Conjugated Linoleic Acid

Conjugated linoleic acid, better known as CLA, is a fatty acid derived from the required nutrient, linoleic acid. The major structural difference between linoleic acid (an 18 carbon, polyunsaturated fatty acid) and CLA, is that linoleic acid has double bonds at carbons 9 and 12 in a cis configuration (methylene interrupted), while CLA has numerous isomers without methylene interrupted conjugate...